QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)

Pliant Therapeutics (PLRX) Competitors

$22.41
-0.36 (-1.58%)
(As of 01:39 PM ET)
Compare
Today's Range
$22.13
$23.09
50-Day Range
$20.99
$30.56
52-Week Range
$6.37
$36.64
Volume
207,819 shs
Average Volume
807,359 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.83

PLRX vs. ETNB, IDYA, AUPH, CPRX, TVTX, LGND, BMEA, CRNX, CTIC, and MNKD

Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include 89bio (ETNB), IDEAYA Biosciences (IDYA), Aurinia Pharmaceuticals (AUPH), Catalyst Pharmaceuticals (CPRX), Travere Therapeutics (TVTX), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), Crinetics Pharmaceuticals (CRNX), CTI BioPharma (CTIC), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.

Pliant Therapeutics vs.

Pliant Therapeutics (NASDAQ:PLRX) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.

In the previous week, 89bio had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 9 mentions for 89bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.20 beat 89bio's score of 0.16 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
89bio
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

89bio has a net margin of 0.00% compared to Pliant Therapeutics' net margin of -1,359.22%. Pliant Therapeutics' return on equity of -39.05% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant Therapeutics -1,359.22% -39.05% -35.16%
89bio N/A -50.72% -40.53%

Pliant Therapeutics presently has a consensus target price of $47.83, indicating a potential upside of 110.07%. 89bio has a consensus target price of $34.00, indicating a potential upside of 68.57%. Given Pliant Therapeutics' higher probable upside, equities analysts clearly believe Pliant Therapeutics is more favorable than 89bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
3.00
89bio
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

97.5% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 87.8% of 89bio shares are owned by institutional investors. 5.6% of Pliant Therapeutics shares are owned by insiders. Comparatively, 4.4% of 89bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pliant Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, 89bio has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

89bio has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$9.69 million139.02-$123.32 million-$2.86-7.96
89bioN/AN/A-$102.03 million-$2.82-7.15

89bio received 40 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 61.29% of users gave Pliant Therapeutics an outperform vote while only 60.94% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
Pliant TherapeuticsOutperform Votes
38
61.29%
Underperform Votes
24
38.71%
89bioOutperform Votes
78
60.94%
Underperform Votes
50
39.06%

Summary

Pliant Therapeutics beats 89bio on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLRX vs. The Competition

MetricPliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.37B$5.84B$4.56B$6.24B
Dividend YieldN/A2.59%2.37%6.18%
P/E Ratio-7.964.0088.1111.48
Price / Sales139.02329.333,480.1888.78
Price / CashN/A20.7991.25113.51
Price / Book3.544.784.695.31
Net Income-$123.32M$189.59M$117.73M$193.03M
7 Day Performance2.52%0.91%1.35%2.06%
1 Month Performance1.16%1.29%1.97%5.85%
1 Year Performance218.02%17.31%9.06%3.51%

Pliant Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETNB
89bio
2.0892 of 5 stars
$17.28
-2.3%
$34.00
+96.8%
+410.6%$1.26BN/A-6.1341Insider Selling
Positive News
IDYA
IDEAYA Biosciences
1.8258 of 5 stars
$21.86
-1.6%
$29.40
+34.5%
+102.0%$1.25B$47.45M-14.3881
AUPH
Aurinia Pharmaceuticals
2.0033 of 5 stars
$9.05
-4.6%
$13.00
+43.6%
-18.7%$1.29B$134.03M-13.51300
CPRX
Catalyst Pharmaceuticals
2.869 of 5 stars
$11.55
+0.4%
$21.50
+86.1%
+70.4%$1.23B$214.20M13.1376
TVTX
Travere Therapeutics
1.9166 of 5 stars
$16.41
-0.1%
$29.85
+81.9%
-27.5%$1.22B$212.02M-3.70310
LGND
Ligand Pharmaceuticals
2.6173 of 5 stars
$69.53
-3.6%
$101.67
+46.2%
-11.9%$1.20B$196.24M55.18154
BMEA
Biomea Fusion
1.4978 of 5 stars
$33.86
+7.7%
$40.29
+19.0%
+464.1%$1.20BN/A-10.5551
CRNX
Crinetics Pharmaceuticals
2.3172 of 5 stars
$22.05
-0.2%
$45.50
+106.3%
+10.4%$1.19B$4.29M-6.72143Insider Buying
News Coverage
Positive News
CTIC
CTI BioPharma
2.0462 of 5 stars
$9.02
-0.3%
$10.29
+14.0%
+44.3%$1.19B$53M-15.5522
MNKD
MannKind
1.7465 of 5 stars
$4.43
-2.4%
$6.50
+46.7%
-13.6%$1.17B$99.77M-15.82348

Related Companies and Tools

This page (NASDAQ:PLRX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -